Charles S.  Ryan net worth and biography

Charles Ryan Biography and Net Worth

President of Quince Therapeutics

Charles Ryan, J.D., Ph.D. has served as Quince’s President since September 2023 and is responsible for the company’s corporate legal activities and intellectual property portfolio, in addition to the international integration of financial and operational activities and ongoing business operations of Quince and the company’s pending completion of its planned acquisition of EryDel SpA. To this role, Dr. Ryan brings an extensive background in pharmaceuticals and biotechnology.

Most notably, he served as Senior Vice President and Chief Intellectual Property Counsel at Forest Laboratories (now AbbVie) for more than 10 years where he managed several intellectual property estates spanning CNS, cardiovascular, gastrointestinal, respiratory, and anti-infective therapeutic areas. He also worked closely with the commercial and development teams, as well as the business development teams at Forest.

Most recently, Dr. Ryan served as President, Chief Executive Officer, and Chairman of Travecta Therapeutics, a private biopharmaceutical company pioneering transformative treatments for serious neurological conditions. Prior to that, he served as Chief Executive Officer and Director of Neurotrope, Inc., a clinical-stage biopharmaceutical company developing targeted, novel regenerative therapeutics for neurodegenerative diseases and developmental disorders.

Dr. Ryan holds a J.D. from Western New England University, a Ph.D. in Oral Biology and Pathology from Stony Brook University, and a B.A. in Chemistry from The College of Wooster. He is a member of the New York State Bar and is a patent practitioner of the U.S. Patent and Trademark Office.

What is Charles S. Ryan's net worth?

The estimated net worth of Charles S. Ryan is at least $10.52 thousand as of August 20th, 2024. Dr. Ryan owns 612 shares of Quince Therapeutics stock worth more than $10,518 as of July 1st. This net worth evaluation does not reflect any other assets that Dr. Ryan may own. Learn More about Charles S. Ryan's net worth.

How do I contact Charles S. Ryan?

The corporate mailing address for Dr. Ryan and other Quince Therapeutics executives is 269 EAST GRAND AVE, SOUTH SAN FRANCISCO CA, 94080. Quince Therapeutics can also be reached via phone at (650) 910-5717 and via email at [email protected]. Learn More on Charles S. Ryan's contact information.

Has Charles S. Ryan been buying or selling shares of Quince Therapeutics?

Charles S. Ryan has not been actively trading shares of Quince Therapeutics during the last ninety days. Most recently, on Tuesday, August 20th, Charles S. Ryan bought 241 shares of Quince Therapeutics stock. The stock was acquired at an average cost of $130.00 per share, with a total value of $31,330.00. Following the completion of the transaction, the president now directly owns 612 shares of the company's stock, valued at $79,560. Learn More on Charles S. Ryan's trading history.

Who are Quince Therapeutics' active insiders?

Quince Therapeutics' insider roster includes Brendan Hannah (Chief Operating Officer & Chief Business Officer), and Charles Ryan (President). Learn More on Quince Therapeutics' active insiders.

Charles S. Ryan Insider Trading History at Quince Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/20/2024Buy241$130.00$31,330.00612View SEC Filing Icon  
See Full Table

Charles S. Ryan Buying and Selling Activity at Quince Therapeutics

This chart shows Charles S Ryan's buying and selling at Quince Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Quince Therapeutics Company Overview

Quince Therapeutics logo
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $16.56
Low: $16.30
High: $18.03

50 Day Range

MA: $22.08
Low: $18.01
High: $27.40

2 Week Range

Now: $16.56
Low: $15.80
High: $909.98

Volume

34,339 shs

Average Volume

286,604 shs

Market Capitalization

$323.91 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.4